Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck.
about
Biomarkers of head and neck cancer, tools or a gordian knot?Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancerCurrent role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinomaGenome stability pathways in head and neck cancersMMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer.Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomasExons 19 and 21 of epidermal growth factor receptor are highly conserved in squamous cell cancer of the head and neckMolecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer.Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neckTongue carcinoma infrequently harbor common actionable genetic alterationsCombination of phosphorylated and truncated EGFR correlates with higher tumor and nodal stage in head and neck cancerScreening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study.Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity.Receptor-tyrosine-kinase-targeted therapies for head and neck cancer.Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.Monitoring response to gefitinib in nude mouse tumor xenografts by (18)F-FDG microPET-CT: correlation between (18)F-FDG uptake and pathological response.Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma.Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy.An Inducible TGF-β2-TGFβR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases.Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.A phase II trial of induction chemotherapy and chemo-IMRT for head and neck squamous cell cancers at risk of bilateral nodal spread: the application of a bilateral superficial lobe parotid-sparing IMRT technique and treatment outcomes.A growing family: adding mutated Erbb4 as a novel cancer targetTumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma.Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trialEGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab.Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma.Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer.Epidermal growth factor receptor inhibition and non-small cell lung cancer.Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancerTargeting epidermal growth factor receptor signaling in the treatment of head and neck cancer.Cetuximab in the treatment of head and neck cancer.Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors.Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis.Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck.Small molecule signal transduction inhibitors for the treatment of solid tumors.Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives.
P2860
Q26784289-64437A74-0575-4649-A6D2-4270A1C818D0Q26852215-05701ED4-EBE0-47BD-A196-4ED8F68654D8Q26991953-00CC9198-B7B0-4711-A52F-FFC8A35FF65CQ28391355-C90B7FDE-7DDC-42C6-A3DD-770D7028A3B6Q33570512-D8584B42-2E25-4CF9-BE4C-6FB0CF0CDAB9Q33575439-E642C4A3-C478-461E-986D-BC0D80018393Q33621754-838A4627-4A01-4757-9574-74113B572DA8Q33843578-5B7375F3-BACB-46D7-8B70-38B1C9F96450Q33947959-CD3A4FF6-FD79-4508-B8B9-F783E67EBF19Q34159125-7C766E3C-AB28-40E4-9081-EF5AF570B9D8Q34256064-CC0FE09E-DC89-4C17-B2B5-E95679FE0B2AQ34318204-8C20FEFF-1973-4D2E-AFF4-28F45516D167Q34497010-0D8B4B95-E91E-4D7C-AD03-B23E20D29342Q34584728-0A21E944-0FB7-4D3E-BA24-89E21580C936Q34618994-1834B8ED-1855-484B-93D8-D59D81364D60Q35016912-60CE86AA-4ED1-45E2-A968-3D92FC1E0489Q35102025-05119EE8-0B64-43E5-A44E-DF9F15A534D8Q35191014-A6FDD719-230E-445D-8399-CB4B52720BB8Q35215449-266FBDD1-A77F-4E95-8561-AA7A2936D9CEQ35471421-ECB79C81-A5E1-4E74-88FD-895CBDAB8637Q35558988-98F1261B-00AC-4836-BDFD-51B7BE6E8833Q35577672-1D083DE0-4052-4BAA-B3DE-57006DAC19BCQ35584647-5F04BA8E-0714-4C33-BEAD-F80BF5F1096AQ35673572-A01E145F-10E4-4EF5-B8F6-120E7C5C32AFQ35677705-3098CD21-4C6F-4DC5-8969-D1F000393345Q36062442-31F3FC15-C868-49CE-BF8D-88F0D3F40610Q36196817-86BE31F3-D692-4A37-95FB-F3C7A29107B9Q36228534-0C254BE4-0080-462A-8069-B4109ECF6687Q36302347-6F6A002E-C5F0-4C9C-9F39-3910B6ADBC84Q36400027-BCF92511-3D8D-4F9A-9BC2-23F85AB59EE3Q36429519-2C0AA802-54D2-4AB9-AFC7-BD893F522695Q36504349-24CF0738-E5AA-4F03-9E90-CF3F7EAFD30FQ36613924-EC9386E1-67F7-4195-8095-D279FD3AC6A0Q36613969-CA012A93-8F02-4B55-B30B-C5861D3EA91FQ36668224-5C56D77A-FC84-4DEF-B62B-D93EBA18E873Q36669662-AADEE683-ED93-4B3F-9CCE-B70A073EB508Q36691733-CD005E1D-2728-425C-BB07-E263DFAEF2ACQ36708974-F2E0876E-039B-48EC-9DF3-688F8E2C5029Q36895413-4F873C78-211E-4438-A3E1-A852D6163667Q36920799-90A96C06-7BF2-414A-9A83-3227CF664DB1
P2860
Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck.
@en
Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck.
@nl
type
label
Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck.
@en
Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck.
@nl
prefLabel
Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck.
@en
Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck.
@nl
P2093
P1476
Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck.
@en
P2093
Dong Il Sun
Hyo Kyung Nam
Ja June Jang
Jong Woo Lee
Jung Young Lee
Min Sik Kim
Nam Jin Yoo
Su Young Kim
Sug Hyung Lee
Suk Woo Nam
P304
P356
10.1158/1078-0432.CCR-04-2029
P407
P577
2005-04-01T00:00:00Z